SCHEMBL25826715

SCHEMBL25826715

Cc1cc(OC(C)C)c2cc(N3CCOCC3)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
KMT2A Q03164 3/20 0.52
MAPK1 P28482 3/20 0.52
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 2/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
NCF1 P14598 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
TDO2 P48775 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25826713 0.89 NCF1 (0.41) MAPTKMT2AMAPK1POLBSMN1; SMN2
SCHEMBL25826714 0.89 NCF1 (0.44) MAPTKMT2AMAPK1POLBMEN1
SCHEMBL25824173 0.86 KMT2A (0.57) MAPTKMT2AMAPK1POLBSMN1; SMN2
SCHEMBL24006170 0.85 MAPT (0.51) MAPTKMT2AMAPK1POLBSMN1; SMN2
SCHEMBL24010843 0.82 MAPT (0.53) MAPTKMT2AMAPK1POLBSMN1; SMN2
SCHEMBL25826716 0.81 CCNC (0.51) MAPTKMT2APOLBSMN1; SMN2MEN1
SCHEMBL23999923 0.79 MAPT (0.60) MAPTKMT2AMAPK1POLBSMN1; SMN2
SCHEMBL29125302 0.78 MAPT (0.48) MAPTKMT2AMAPK1POLBSMN1; SMN2
SCHEMBL23999557 0.78 KMT2A (0.54) MAPTKMT2AMAPK1POLBSMN1; SMN2
SCHEMBL29125442 0.78 KMT2A (0.57) MAPTKMT2AMAPK1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPT 3999/4885KMT2A 3974/4885MAPK1 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.